MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-01-2026
China Pharma Holdings EPS Ratio 2011-2026 | CPHI
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio China Pharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.74 | -2.71 | -0.91 | -3.78 | -0.74 | -0.07 | -0.48 | -0.25 | -0.44 | -0.21 | -0.35 | -0.91 | -0.46 | 0.11 | 0.44 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.44 | -3.78 | -0.767 |
Quarterly EPS Ratio China Pharma Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.17 | -0.16 | -0.24 | - | -0.65 | -0.89 | -0.72 | - | -0.29 | -0.35 | -0.06 | - | -0.16 | -0.18 | -0.22 | - | -0.02 | -0.02 | -0.02 | - | -0.02 | - | -0.02 | - | -0.02 | -0.02 | -0.01 | - | -0.04 | -0.02 | -0.01 | - | -0.05 | -0.05 | -0.02 | - | -0.04 | -0.06 | -0.04 | - | 0.07 | 0.03 | -0.09 | - | -0.15 | -0.2 | -0.05 | - | -0.05 | -0.1 | -0.06 | - | 0.03 | 0.04 | 0.06 | - | 0.11 | 0.12 | 0.12 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.12 | -0.89 | -0.107 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Drug manufacturers industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-0.34 | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.61 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-6.71 | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-0.18 | - | 0.86 % | $ 117 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-0.14 | $ 4.25 | 4.68 % | $ 59.8 M | USA |
 |
Catalent
CTLT
|
-5.76 | - | - | $ 11.5 B | USA |
 |
Alimera Sciences
ALIM
|
-0.84 | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-15.8 | - | -23.39 % | $ 1.76 M | USA |
 |
DURECT Corporation
DRRX
|
-1.05 | - | - | $ 50.1 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.79 | $ 1.09 | -4.39 % | $ 1.35 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.76 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-10.4 | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
-0.51 | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-2.33 | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-9.66 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Tilray
TLRY
|
-2.35 | $ 6.88 | 1.9 % | $ 4.25 B |  Canada |
 |
HEXO Corp.
HEXO
|
-0.89 | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
-1.62 | $ 5.62 | -0.18 % | $ 2.05 B | Canada |
 |
Jupiter Wellness
JUPW
|
-17 | - | - | $ 33.6 M | USA |
 |
Veru
VERU
|
-0.28 | $ 2.34 | -0.43 % | $ 316 M | USA |
 |
Canopy Growth Corporation
CGC
|
-5.56 | $ 1.21 | 1.69 % | $ 130 M | Canada |
 |
Harrow Health
HROW
|
-0.14 | $ 41.31 | 4.06 % | $ 1.52 B | USA |
 |
Viatris
VTRS
|
0.05 | $ 14.89 | 2.02 % | $ 17.9 B | USA |
 |
Lannett Company
LCI
|
-5.74 | - | 1.15 % | $ 7.11 M | USA |
 |
Solid Biosciences
SLDB
|
-1.99 | $ 7.53 | -4.92 % | $ 659 M | USA |
 |
OrganiGram Holdings
OGI
|
-0.51 | $ 1.45 | 0.43 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-0.01 | $ 2.38 | 1.28 % | $ 313 M | USA |
 |
Evolus
EOLS
|
-0.8 | $ 5.24 | -1.13 % | $ 338 M | USA |
 |
Sundial Growers
SNDL
|
-1.1 | $ 1.54 | 1.66 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-14.8 | $ 8.05 | 0.25 % | $ 412 M | USA |
 |
Pacira BioSciences
PCRX
|
-2.15 | $ 25.31 | 3.26 % | $ 1.17 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
-4.24 | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
1.17 | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
-1.79 | $ 0.99 | -2.11 % | $ 4.27 M | USA |
 |
Radius Health
RDUS
|
-1.49 | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
-4.74 | $ 18.08 | 0.19 % | $ 116 M | USA |
 |
PetIQ
PETQ
|
0.07 | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-1.45 | $ 7.06 | -2.15 % | $ 279 M | USA |
 |
Recro Pharma
REPH
|
-0.14 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-0.32 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-0.17 | $ 1.02 | 0.49 % | $ 50.9 M | USA |
 |
PLx Pharma
PLXP
|
-2.06 | - | -27.8 % | $ 2.56 M | USA |
 |
Aurora Cannabis
ACB
|
-4.1 | $ 3.5 | 3.24 % | $ 86.3 M | Canada |
 |
Zomedica Corp.
ZOM
|
-0.08 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-0.82 | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-0.15 | $ 0.85 | -3.14 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-3.44 | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
-0.05 | $ 2.16 | -1.37 % | $ 25 M | USA |